GlaxoSmithKline's Japanese subsidiary
Part of GSK
CompanyJapan
GlaxoSmithKline's Japanese subsidiary develops one asset. Mostly oligonucleotide; based in Japan.
- 1
- Asset
- Furthest stage
- Not known
- 0
- Trials
- 0
- Signals
Pipeline
1Targets hepatitis B viral RNA to reduce viral proteins and replication.
Stage not known, Oligonucleotide
Full company profiles: pipeline, trials, funding and people.